Albireo

<!-- Name:DistributionId Value:8748493 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

- Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU - ASSERT study demonstrated efficacy of Bylvay (odevixibat) in pruritus, bile acids and sleep with a…

– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS) – Oral late breaker provides evidence of disease modification in PFIC –…

Amélioration statistiquement significative du critère d'évaluation primaire du prurit (p = 0,002).Réductions significatives du critère d'évaluation secondaire des niveaux d'acides biliaires…

Hochgradige statistisch signifikante Linderung von Juckreiz, dem primären Endpunkt (p=0,002)Signifikante Verringerung des Gallensäurespiegels im Serum, dem wichtigsten sekundären Endpunkt…

Miglioramento statisticamente molto significativo dell'endpoint primario del prurito (p=0,002)Significative riduzioni dell'endpoint chiave secondario dei livelli di acidi biliari nel siero…

Mejoría estadísticamente muy significativa en el criterio de valoración principal «prurito» (p = 0,002)Reducciones significativas en el criterio de valoración secundario clave «niveles de…

– New data presented at the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition meeting (NASPGHAN) – Earlier treatment with Bylvay (odevixibat) provided…

Highly statistically significant improvement in pruritus primary endpoint (p=0.002)Significant reductions in key secondary endpoint of serum bile acid levels (p=0.001)Substantial…

– Seven abstracts accepted, including one oral presentation highlighting long-term data demonstrating Bylvay® (odevixibat) durable efficacy in patients with all types of PFIC – One…